Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 16
2.1 What is This Report About? 16
3 In Vitro Diagnostics In Canada 17
3.1 In Vitro Diagnostics, Market Segmentation 17
3.2 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017 18
3.3 In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2010 20
3.4 In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010 21
3.5 In Vitro Diagnostics, Canada, Company share (2009-2010) 28
4 Clinical Chemistry In Canada 30
4.1 Clinical Chemistry, Market Segmentation 30
4.2 Clinical Chemistry Market, Canada, Revenue Mix ($m), 2010 31
4.3 Clinical Chemistry Market, Canada, Segment Contribution (%), 2010 32
4.4 Clinical Chemistry Overall Revenue (2003-2017) 33
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 37
4.4.2 Urine Analysis Revenue (2003-2017) 41
4.5 Clinical Chemistry Distribution Share (2009-2010) 45
4.6 Clinical Chemistry, Canada, Company share (2009-2010) 46
5 Genetic Testing In Canada 48
5.1 Genetic Testing, Market Segmentation 48
5.2 Genetic Testing Market, Canada, Revenue Mix ($m), 2010 49
5.3 Genetic Testing Market, Canada, Segment Contribution (%), 2010 50
5.4 Genetic Testing Overall Revenue (2003-2017) 51
5.5 Genetic Testing Distribution Share (2009-2010) 55
5.6 Genetic Testing, Canada, Company share (2009-2010) 56
6 Haematology In Canada 58
6.1 Haematology, Market Segmentation 58
6.2 Haematology Market, Canada, Revenue Mix ($m), 2010 59
6.3 Haematology Market, Canada, Segment Contribution (%), 2010 60
6.4 Haematology Overall Revenue (2003-2017) 61
6.4.1 Haematology Reagents Revenue (2003-2017) 65
6.4.2 Immunohaematology Revenue (2003-2017) 69
6.4.3 Haemostasis Revenue (2003-2017) 73
6.4.4 Haematology Rapid Tests Revenue (2003-2017) 77
6.4.5 Haematology Cell Counters Revenue (2003-2017) 81
6.5 Haematology Distribution Share (2009-2010) 85
6.6 Haematology, Canada, Company share (2009-2010) 86
7 Histology And Cytology In Canada 88
7.1 Histology And Cytology, Market Segmentation 88
7.2 Histology And Cytology Market, Canada, Revenue Mix ($m), 2010 89
7.3 Histology And Cytology Market, Canada, Segment Contribution (%), 2010 90
7.4 Histology And Cytology Overall Revenue (2003-2017) 91
7.5 Histology And Cytology Distribution Share (2009-2010) 95
7.6 Histology And Cytology, Canada, Company share (2009-2010) 96
8 Immuno Chemistry In Canada 98
8.1 Immuno Chemistry Market, Canada, Revenue Mix ($m), 2010 98
8.2 Immuno Chemistry Market, Canada, Segment Contribution (%), 2010 99
8.3 Immuno Chemistry Overall Revenue (2003-2017) 101
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 105
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 109
8.3.3 Endocrinology Tests Revenue (2003-2017) 113
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 117
8.3.5 Immunochemistry Analyzers Revenue (2003-2017) 121
8.4 Immuno Chemistry Distribution Share (2009-2010) 125
8.5 Immuno Chemistry, Canada, Company share (2009-2010) 126
9 Infectious Immunology In Canada 128
9.1 Infectious Immunology, Market Segmentation 128
9.2 Infectious Immunology Market, Canada, Revenue Mix ($m), 2010 129
9.3 Infectious Immunology Market, Canada, Segment Contribution (%), 2010 130
9.4 Infectious Immunology Overall Revenue (2003-2017) 131
9.5 Infectious Immunology Distribution Share (2009-2010) 135
9.6 Infectious Immunology, Canada, Company share (2009-2010) 136
10 Microbiology Culture In Canada 138
10.1 Microbiology Culture, Market Segmentation 138
10.2 Microbiology Culture Market, Canada, Revenue Mix ($m), 2010 139
10.3 Microbiology Culture Market, Canada, Segment Contribution (%), 2010 140
10.4 Microbiology Culture Overall Revenue (2003-2017) 141
10.4.1 Microbiology Analyzers Revenue (2003-2017) 145
10.5 Microbiology Culture Distribution Share (2009-2010) 149
10.6 Microbiology Culture, Canada, Company share (2009-2010) 150
11 Overview of Key Companies in Canada In Vitro Diagnostics Market 152
11.1 Siemens Healthcare 152
11.1.1 Company Overview 152
11.1.2 Share in the Canada In Vitro Diagnostics Market 152
11.2 Abbott Laboratories 153
11.2.1 Company Overview 153
11.2.2 Share in the Canada In Vitro Diagnostics Market 153
11.3 F. Hoffmann-La Roche Ltd. 154
11.3.1 Company Overview 154
11.3.2 Share in the Canada In Vitro Diagnostics Market 154
11.4 Beckman Coulter, Inc. 155
11.4.1 Company Overview 155
11.4.2 Share in the Canada In Vitro Diagnostics Market 155
11.5 Ortho-Clinical Diagnostics Inc. 156
11.5.1 Company Overview 156
11.5.2 Share in the Canada In Vitro Diagnostics Market 156
11.6 bioMerieux S.A. 157
11.6.1 Company Overview 157
11.6.2 Share in the Canada In Vitro Diagnostics Market 157
11.7 Becton, Dickinson and Company 158
11.7.1 Company Overview 158
11.8 Bio-Rad Laboratories, Inc. 158
11.8.1 Company Overview 158
11.9 Biomedica Diagnostics Inc. 158
11.9.1 Company Overview 158
11.10 Sysmex Corporation 159
11.10.1 Company Overview 159
11.11 Qiagen N.V. 159
11.11.1 Company Overview 159
11.12 Immucor, Inc. 159
11.12.1 Company Overview 159
11.13 Alere Inc. 160
11.13.1 Company Overview 160
11.14 Gen-Probe Incorporated 160
11.14.1 Company Overview 160
11.15 DiaSorin S.p.A 161
11.15.1 Company Overview 161
11.16 Thermo Fisher Scientific Inc. 161
11.16.1 Company Overview 161
11.17 Phadia AB 161
11.17.1 Company Overview 161
11.18 Hologic, Inc. 162
11.18.1 Company Overview 162
11.19 Grifols, S.A. 162
11.19.1 Company Overview 162
11.20 Life Technologies Corporation 163
11.20.1 Company Overview 163
11.21 HORIBA, Ltd. 163
11.21.1 Company Overview 163
11.22 PerkinElmer, Inc. 164
11.22.1 Company Overview 164
12 In Vitro Diagnostics Market Pipeline Products 165
12.1 Clinical Chemisty Market Pipeline Products 165
12.2 Immuno Chemistry Market Pipeline Products 168
12.3 Haematology Market Pipeline Products 171
12.4 Infectious Immunology Market Pipeline Products 173
12.5 Microbiology Culture Market Pipeline Products 176
12.6 Histology And Cytology Market Pipeline Products 177
12.7 Genetic Testing Market Pipeline Products 178
13 Financial Deals Landscape 181
13.1 Merger 181
13.1.1 Transonic Systems Merges with Scisense 181
13.2 Acquisition 183
13.2.1 Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies 183
13.2.2 OraSure Technologies Completes Acquisition Of DNA Genotek 184
13.2.3 Trinity Biotech Acquires Phoenix Bio-Tech 186
13.3 Partnerships 187
13.3.1 Sony DADC Enters Into Co-Development Agreement With Axela 187
13.3.2 Genome British Columbia Enters Into Co-Development Agreement With Genome Canada 188
13.3.3 WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics 189
13.3.4 Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics 190
13.3.5 Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada 191
13.3.6 Warnex Enters Into Licensing Agreement With Sorenson Forensics 192
13.3.7 Roche Enters Into Distribution Agreement With PerkinElmer 193
13.3.8 Pronexus Enters Into Technology Integration Agreement With RealityCorp 194
13.3.9 Carl Zeiss Enters Into Licensing Agreement With Prior Scientific 195
13.3.10 Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical 196
13.3.11 Signal Genetics Enters Into Research And Development Agreement With DiagnoCure 197
13.3.12 Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics 198
13.3.13 Mitomics Enters Into Licensing Agreement With QDx Pathology Services 199
13.3.14 Biofortuna Enters Into Distribution Agreement With Abbott 200
13.3.15 CML HealthCare Enters Into Licensing Agreement With Phenomenome Discoveries 201
13.3.16 Magellan BioScience Enters Into An Agreement With miacom diagnostics 202
13.3.17 Affymetrix Enters Into Distribution Agreement With Thermo Fisher 203
14 Recent Developments 204
14.1 Strategy and Business Planning 204
14.1.1 Dec 20, 2011: Warnex To Sell Analytical Services Division 204
14.1.2 Nov 30, 2011: SQI Diagnostics Announces Realignment Of Business And Reductions In Operating Expenses To Better Serve Its IVD And CustomPlex Businesses 204
14.1.3 Oct 04, 2011: Roche To Expand Coagulation Testing Portfolio, Develop New Systems For Diagnostic Laboratories In US And Canada By 2014 205
14.1.4 May 26, 2011: New England Biolabs Opens New Subsidiary Office In France 205
14.1.5 Mar 14, 2011: Pacgen Announces Corporate Transformation 206
14.2 Legal and Regulatory 206
14.2.1 Feb 24, 2011: Med Biogene Charged With Fraud and Precision Therapeutics Charged With Tortious Interference In Amended Complaint by Signal Genetics 206
14.3 Government and Public Interest 207
14.3.1 Dec 21, 2011: Miraculins Successfully Passes Critical ISO 13485 Certification Audit 207
14.3.2 Oct 05, 2011: Norgen Biotek Achieves Accreditation To ISO 15189:2007 For Molecular Diagnostic Testing And Clinical Trials 207
14.3.3 Sep 21, 2011: Aeterna Zentaris To Present At Sixth Annual JMP Securities Healthcare Conference 208
14.3.4 Aug 02, 2011: Noninvasive Fecal Occult Blood Test Effective Screen For Lower GI Tract Lesions: Study 208
14.3.5 Jul 28, 2011: Verisante Obtains ISO Certification Of Quality Management System For Medical Device Manufacturing 209
14.3.6 Jul 04, 2011: UBC's Megapixel DNA Replication Technology Promises Faster, More Precise Diagnostics 209
14.3.7 Jun 16, 2011: Researchers At Queen's University Develop First Diagnostic Test For Hereditary Children's Disease 210
14.4 Product News 210
14.4.1 Dec 19, 2011: British Columbia Cancer Agency Joins Illumina Genome Network 210
14.4.2 Oct 12, 2011: Affymetrix Releases Axiom Genome-Wide Pan-African Array 211
14.4.3 Oct 12, 2011: GeneDx Unveils XomeDx Test To Identify Rare Inherited Diseases 212
14.4.4 Oct 12, 2011: NanoString Launches Second Generation nCounter Analysis System 213
14.4.5 Oct 11, 2011: RainDance Technologies Launches ThunderStorm System At 12th ICHG In Montreal, Canada 213
14.4.6 Aug 31, 2011: CaridianBCT Launches Mononuclear Cell Collection Protocol For Spectra Optia Apheresis System In Canada 214
14.4.7 Aug 30, 2011: Aeterna Zentaris Announces Favorable Top-Line Results Of Completed Phase III Study On AEZS-130 As First Oral Diagnostic Test For Adult Growth Hormone Deficiency 214
14.4.8 Aug 22, 2011: Gen-Probe Receives Canadian Regulatory Clearance For PANTHER System 216
14.4.9 Aug 18, 2011: RPS Receives Health Canada Approval For RPS InflammaDry Detector 216
14.4.10 Jul 15, 2011: Sentinel Principle Used To Discover Blood Based Biomarkers To Predict Risk Of Liver Cancer From Patients With Chronic Hepatitis: GeneNews 217
14.4.11 Jul 06, 2011: Axial Biotech Signs Agreement With Shriners Hospital for Children To Provide SCOLISCORE AIS Prognostic Test 218
14.4.12 May 06, 2011: DiagnoCure To Present Previstage GCC Test At ASCRS In Canada 218
14.4.13 Feb 22, 2011: CardioGenics Receives Canadian Patent For QL Care Analyzer Core Technology 219
14.4.14 Feb 08, 2011: PinPointe Receives FDA Approval For PinPointe FootLaser In Canada 219
15 Appendix 220
15.1 Definitions of Markets Covered in the Report 221
15.1.1 In Vitro Diagnostics 221
15.2 Research Methodology 231
15.3 Secondary Research 231
15.4 Primary Research 232
15.5 Models 232
15.6 Forecasts 233
15.7 Expert Panels 233
15.8 GlobalData Consulting 233
15.9 Currency Conversion 234
15.10 Contact Us 234
15.11 Disclaimer 234
List of Tables
Table 1: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017 19
Table 2: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010 21
Table 3: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2003-2017 23
Table 4: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010 25
Table 5: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 27
Table 6: In Vitro Diagnostics, Canada, Company share by Revenue ($m), USD Actual, 2009-2010 29
Table 7: Clinical Chemistry Market, Canada, Segment Contribution (%), 2010 32
Table 8: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 34
Table 9: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 36
Table 10: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 38
Table 11: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 40
Table 12: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 42
Table 13: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 44
Table 14: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 45
Table 15: Clinical Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010 47
Table 16: Genetic Testing Market, Canada, Segment Contribution (%), 2010 50
Table 17: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 52
Table 18: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 54
Table 19: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 55
Table 20: Genetic Testing, Canada, Company share by Revenue ($m), USD Actual 2009-2010 57
Table 21: Haematology Market, Canada, Segment Contribution (%), 2010 60
Table 22: Haematology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 62
Table 23: Haematology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 64
Table 24: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 66
Table 25: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 68
Table 26: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 70
Table 27: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 72
Table 28: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 74
Table 29: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 76
Table 30: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 78
Table 31: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 80
Table 32: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 82
Table 33: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 84
Table 34: Haematology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 85
Table 35: Haematology, Canada, Company share by Revenue ($m), USD Actual 2009-2010 87
Table 36: Histology And Cytology Market, Canada, Segment Contribution (%), 2010 90
Table 37: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 92
Table 38: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 94
Table 39: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 40: Histology And Cytology, Canada, Company share by Revenue ($m), USD Actual 2009-2010 97
Table 41: Immuno Chemistry Market, Canada, Segment Contribution (%), 2010 100
Table 42: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 102
Table 43: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 104
Table 44: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 106
Table 45: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 108
Table 46: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 110
Table 47: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 112
Table 48: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114
Table 49: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116
Table 50: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 118
Table 51: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 120
Table 52: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 122
Table 53: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 124
Table 54: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 125
Table 55: Immuno Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010 127
Table 56: Infectious Immunology Market, Canada, Segment Contribution (%), 2010 130
Table 57: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 132
Table 58: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 134
Table 59: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 135
Table 60: Infectious Immunology, Canada, Company share by Revenue ($m), USD Actual 2009-2010 137
Table 61: Microbiology Culture Market, Canada, Segment Contribution (%), 2010 140
Table 62: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 142
Table 63: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 144
Table 64: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 146
Table 65: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 148
Table 66: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010 149
Table 67: Microbiology Culture, Canada, Company share by Revenue ($m), USD Actual 2009-2010 151
Table 68: Clinical Chemisty Market Pipeline Products 165
Table 69: Immuno Chemistry Market Pipeline Products 168
Table 70: Haematology Market Pipeline Products 171
Table 71: Infectious Immunology Market Pipeline Products 173
Table 72: Microbiology Culture Market Pipeline Products 176
Table 73: Histology And Cytology Market Pipeline Products 177
Table 74: Genetic Testing Market Pipeline Products 178
Table 75: Transonic Systems Merges With Scisense 181
Table 76: Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies 183
Table 77: OraSure Technologies Completes Acquisition Of DNA Genotek 184
Table 78: Trinity Biotech Acquires Phoenix Bio-Tech 186
Table 79: Sony DADC Enters Into Co-Development Agreement With Axela 187
Table 80: Genome British Columbia Enters Into Co-Development Agreement With Genome Canada 188
Table 81: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics 189
Table 82: Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics 190
Table 83: Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada 191
Table 84: Warnex Enters Into Licensing Agreement With Sorenson Forensics 192
Table 85: Roche Enters Into Distribution Agreement With PerkinElmer 193
Table 86: Pronexus Enters Into Technology Integration Agreement With RealityCorp 194
Table 87: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific 195
Table 88: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical 196
Table 89: Signal Genetics Enters Into Research And Development Agreement With DiagnoCure 197
Table 90: Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics 198
Table 91: Mitomics Enters Into Licensing Agreement With QDx Pathology Services 199
Table 92: Biofortuna Enters Into Distribution Agreement With Abbott 200
Table 93: CML HealthCare Enters Into Licensing Agreement With Phenomenome Discoveries 201
Table 94: Magellan BioScience Enters Into An Agreement With miacom diagnostics 202
Table 95: Affymetrix Enters Into Distribution Agreement With Thermo Fisher 203
Table 96: USD to Local Currency, Canada, Average Actual Rate 2003-2010 234
List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 17
Figure 2: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017 18
Figure 3: In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2010 20
Figure 4: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2010 21
Figure 5: In Vitro Diagnostics, Canada, Cross-Category Analysis, 2003-2017 22
Figure 6: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010 24
Figure 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 26
Figure 8: In Vitro Diagnostics, Canada, Company share (%), 2010 28
Figure 9: Clinical Chemistry, Market Segmentation 30
Figure 10: Clinical Chemistry Market, Canada, Revenue Mix ($m), 2010 31
Figure 11: Clinical Chemistry Market, Canada, Segment Contribution (%), 2010 32
Figure 12: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 33
Figure 13: Clinical Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 35
Figure 14: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 37
Figure 15: Clinical Chemisty Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 39
Figure 16: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 41
Figure 17: Urine Analysis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 43
Figure 18: Clinical Chemistry, Canada, Company share (%), 2010 46
Figure 19: Genetic Testing, Market Segmentation 48
Figure 20: Genetic Testing Market, Canada, Revenue Mix ($m), 2010 49
Figure 21: Genetic Testing Market, Canada, Segment Contribution (%), 2010 50
Figure 22: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 51
Figure 23: Genetic Testing, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 53
Figure 24: Genetic Testing, Canada, Company share (%), 2010 56
Figure 25: Haematology, Market Segmentation 58
Figure 26: Haematology Market, Canada, Revenue Mix ($m), 2010 59
Figure 27: Haematology Market, Canada, Segment Contribution (%), 2010 60
Figure 28: Haematology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 61
Figure 29: Haematology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 63
Figure 30: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 65
Figure 31: Haematology Reagents, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 67
Figure 32: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 69
Figure 33: Immunohaematology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 71
Figure 34: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 73
Figure 35: Haemostasis, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 75
Figure 36: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 77
Figure 37: Haematology Rapid Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 79
Figure 38: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 81
Figure 39: Haematology Cell Counters, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 83
Figure 40: Haematology, Canada, Company share (%), 2010 86
Figure 41: Histology And Cytology, Market Segmentation 88
Figure 42: Histology And Cytology Market, Canada, Revenue Mix ($m), 2010 89
Figure 43: Histology And Cytology Market, Canada, Segment Contribution (%), 2010 90
Figure 44: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 91
Figure 45: Histology And Cytology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 93
Figure 46: Histology And Cytology, Canada, Company share (%), 2010 96
Figure 47: Immuno Chemistry Market, Canada, Revenue Mix ($m), 2010 98
Figure 48: Immuno Chemistry Market, Canada, Segment Contribution (%), 2010 99
Figure 49: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 101
Figure 50: Immuno Chemistry, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 103
Figure 51: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 105
Figure 52: Disease Specific Immunochemistry, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 107
Figure 53: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 109
Figure 54: Drugs of Abuse / Toxicology, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 111
Figure 55: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 113
Figure 56: Endocrinology Tests, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 115
Figure 57: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 117
Figure 58: Therapeutic Drug Monitoring, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 119
Figure 59: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 121
Figure 60: Immunochemistry Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 123
Figure 61: Immuno Chemistry, Canada, Company share (%), 2010 126
Figure 62: Infectious Immunology, Market Segmentation 128
Figure 63: Infectious Immunology Market, Canada, Revenue Mix ($m), 2010 129
Figure 64: Infectious Immunology Market, Canada, Segment Contribution (%), 2010 130
Figure 65: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 131
Figure 66: Infectious Immunology, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 133
Figure 67: Infectious Immunology, Canada, Company share (%), 2010 136
Figure 68: Microbiology Culture, Market Segmentation 138
Figure 69: Microbiology Culture Market, Canada, Revenue Mix ($m), 2010 139
Figure 70: Microbiology Culture Market, Canada, Segment Contribution (%), 2010 140
Figure 71: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 141
Figure 72: Microbiology Culture, Canada, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 143
Figure 73: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 145
Figure 74: Microbiology Analyzers, Canada, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 147
Figure 75: Microbiology Culture, Canada, Company share (%), 2010 150
Figure 76: Siemens Healthcare, Company Share (%),Canada In Vitro Diagnostics Market, 2010 152
Figure 77: Abbott Laboratories, Company Share (%),Canada In Vitro Diagnostics Market, 2010 153
Figure 78: F. Hoffmann-La Roche Ltd., Company Share (%),Canada In Vitro Diagnostics Market, 2010 154
Figure 79: Beckman Coulter, Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2010 155
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2010 156
Figure 81: bioMerieux S.A., Company Share (%),Canada In Vitro Diagnostics Market, 2010 157